Published in Acta Pathol Microbiol Immunol Scand Suppl on January 01, 1984
Specific binding of the human S protein (vitronectin) to streptococci, Staphylococcus aureus, and Escherichia coli. Infect Immun (1987) 1.90
Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J (1985) 1.56
Persistent complement activation on tumor cells in breast cancer. Am J Pathol (1992) 1.48
Physicochemical characterization of human S-protein and its function in the blood coagulation system. Biochem J (1985) 1.38
Isolation and characterization of a membrane-attack-complex-inhibiting protein present in human serum and other biological fluids. Biochem J (1990) 1.22
Meningococcal disease and the complement system. Virulence (2013) 1.19
Binding of vitronectin by the Moraxella catarrhalis UspA2 protein interferes with late stages of the complement cascade. Infect Immun (2006) 1.10
Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9. Clin Exp Immunol (1993) 1.09
Animal models for pathogenic Neisseria species. Clin Microbiol Rev (1989) 1.00
Sublytic membrane-attack-complex (MAC) activation alters regulated rather than constitutive vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelium monolayers. J Biol Chem (2011) 0.99
Self-protection of cytotoxic lymphocytes: a soluble form of homologous restriction factor in cytoplasmic granules. Proc Natl Acad Sci U S A (1988) 0.89
Binding of S protein by Neisseria gonorrhoeae and potential role in invasion. J Clin Microbiol (1991) 0.86
Conserved Patterns of Microbial Immune Escape: Pathogenic Microbes of Diverse Origin Target the Human Terminal Complement Inhibitor Vitronectin via a Single Common Motif. PLoS One (2016) 0.81
Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal-complement complex and the vitronectin-thrombin-antithrombin complex. Infect Immun (1994) 0.80
Increased levels of plasma vitronectin in severe psoriatic patients. Arch Dermatol Res (1992) 0.78
Pseudomonas aeruginosa Uses Dihydrolipoamide Dehydrogenase (Lpd) to Bind to the Human Terminal Pathway Regulators Vitronectin and Clusterin to Inhibit Terminal Pathway Complement Attack. PLoS One (2015) 0.78
Vitronectin-binding staphylococci enhance surface-associated complement activation. Infect Immun (1997) 0.77
Endogenous cleavage of the Arg-379-Ala-380 bond in vitronectin results in a distinct conformational change which 'buries' Ser-378, its site of phosphorylation by protein kinase A. Biochem J (1991) 0.77
Binding of vitronectin and clusterin by coagulase-negative staphylococci interfering with complement function. J Mater Sci Mater Med (2004) 0.76
Complement factor H, vitronectin, and opticin are tyrosine-sulfated proteins of the retinal pigment epithelium. PLoS One (2014) 0.76
Killing of Microbes and Cancer by the Immune System with Three Mammalian Pore-Forming Killer Proteins. Front Immunol (2016) 0.75
Targeting of exon VI-skipping human RGR-opsin to the plasma membrane of pigment epithelium and co-localization with terminal complement complex C5b-9. Mol Vis (2016) 0.75
Role of tyrosine-sulfated proteins in retinal structure and function. Exp Eye Res (2015) 0.75
Inhibition of the Membrane Attack Complex by Dengue Virus NS1 through Interaction with Vitronectin and Terminal Complement Proteins. J Virol (2016) 0.75
Retinal Pre-Conditioning by CD59a Knockout Protects against Light-Induced Photoreceptor Degeneration. PLoS One (2016) 0.75
Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature (1994) 11.22
Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med (1977) 7.89
Human monocytes: distinct receptor sites for the third component of complement and for immunoglobulin G. Science (1968) 7.70
Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med (1969) 7.43
The C3-activator system: an alternate pathway of complement activation. J Exp Med (1971) 7.07
C3 proactivator convertase and its mode of action. J Exp Med (1972) 6.94
Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J Exp Med (1967) 6.72
Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J Immunol (1970) 6.58
Complement. Annu Rev Biochem (1975) 6.00
The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement. J Exp Med (1968) 5.78
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Enharncement of the hemolytic activity of the second component of human complement by oxidation. J Exp Med (1967) 5.36
Chemistry and reaction mechanisms of complement. Adv Immunol (1968) 5.02
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A (1978) 4.94
The reaction mechanism of human C5 in immune hemolysis. J Exp Med (1970) 3.83
The second component of human complement: its isolation, fragmentation by C'1 esterase, and incorporation into C'3 convertase. J Exp Med (1968) 3.71
Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest (1970) 3.55
Complement. Annu Rev Biochem (1969) 3.51
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Anaphylatoxins: C3a and C5a. Adv Immunol (1978) 3.44
Molecular biology and chemistry of the alternative pathway of complement. Adv Immunol (1980) 3.41
Molecular analysis of the membrane attack mechanism of complement. J Exp Med (1972) 3.35
Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules. Proc Natl Acad Sci U S A (1985) 3.31
Deficiency of the fifth component of complement in mice with an inherited complement defect. J Exp Med (1967) 3.28
Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J Immunol (1971) 3.25
C1q deviation test for the detection of immune complexes, aggregates of IgG, and bacterial products in human serum. J Exp Med (1975) 3.21
Lysis of erythrocytes by complement in the absence of antibody. J Exp Med (1970) 3.19
Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor. J Exp Med (1975) 3.12
Hemolytic activity of lipoprotein-depleted serum and the effect of certain anions on complement. J Immunol (1966) 2.98
The ninth component of human complement: isolation, description and mode of action. Immunology (1969) 2.96
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med (1980) 2.94
Fourth component of human complement: description of a three polypeptide chain structure. J Exp Med (1974) 2.93
Studies on the mode of action of the fifth, sixth and seventh component of human complement in immune haemolysis. Immunology (1967) 2.93
Paroxysmal nocturnal hemoglobinuria. Hemolysis initiated by the C3 activator system. N Engl J Med (1972) 2.91
Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med (1981) 2.88
Cytolytic T cell granules. Isolation, structural, biochemical, and functional characterization. J Exp Med (1984) 2.86
Cytolysis by H-2-specific T killer cells. Assembly of tubular complexes on target membranes. J Exp Med (1983) 2.78
The role of properdin in the alternate pathway of complement activation. J Exp Med (1974) 2.77
Deficiency of the sixth component of complement in rabbits with an inherited complement defect. J Exp Med (1966) 2.73
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J Exp Med (1976) 2.66
The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med (1973) 2.64
Assembly of two types of tubules with putative cytolytic function by cloned natural killer cells. Nature (1983) 2.62
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J Immunol (1979) 2.58
The membrane attack complex of complement. Annu Rev Immunol (1986) 2.57
Initiation of the alternative pathway of complement: recognition of activators by bound C3b and assembly of the entire pathway from six isolated proteins. Proc Natl Acad Sci U S A (1978) 2.57
Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med (1973) 2.50
Structure and function of human perforin. Nature (1988) 2.47
The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution. J Exp Med (1973) 2.44
A comparison of methods for the molecular quantitation of the fourth component of human complement. Immunochemistry (1968) 2.44
Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci U S A (1986) 2.39
Bactericidal activity of the alternative complement pathway generated from 11 isolated plasma proteins. J Exp Med (1979) 2.39
Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity. Cell (1986) 2.38
Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature (1982) 2.35
Metabolism of third complement component (C3) in nephritis. Involvement of the classic and alternate (properdin) pathways for complement activation. N Engl J Med (1972) 2.33
The eighth component of human complement (C8): isolation, characterization, and hemolytic efficiency. J Exp Med (1969) 2.25
The ninth component of complement and the pore-forming protein (perforin 1) from cytotoxic T cells: structural, immunological, and functional similarities. Science (1986) 2.21
The second component of human complement (C2): quantitative molecular analysis of its reactions in immune hemolysis. Immunochemistry (1970) 2.18
Cytotoxic effects of leukocyres triggered by complement bound to target cells. Science (1969) 2.15
Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function. J Exp Med (1976) 2.13
Complement: substitution of the terminal component in immune hemolysis by 1,10-phenanthroline. Science (1967) 2.11
A molecular concept of the properdin pathway. Proc Natl Acad Sci U S A (1976) 2.09
The ninth component of human complement: purification and physicochemical characterization. J Immunol (1980) 2.09
C1q protein of human complement. Biochemistry (1972) 2.06
Blood coagulation initiation by a complement-mediated pathway. J Exp Med (1971) 2.04
Purification of the sixth and seventh component of human complement without loss of hemolytic activity. J Immunol (1976) 2.02
The alternative pathway of complement. Springer Semin Immunopathol (1984) 2.01
Nucleotide sequence of cDNA and derived amino acid sequence of human complement component C9. Proc Natl Acad Sci U S A (1984) 2.01
Interaction of target cell-bound C3bi and C3d with human lymphocyte receptors. Enhancement of antibody-mediated cellular cytotoxicity. J Exp Med (1981) 1.99
Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat Med (1996) 1.99
A blood coagulation abnormality in rabbits deficient in the sixth component of complement (C6) and its correction by purified C6. J Exp Med (1971) 1.97
Polymerization of the ninth component of complement (C9): formation of poly(C9) with a tubular ultrastructure resembling the membrane attack complex of complement. Proc Natl Acad Sci U S A (1982) 1.96
Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembly. J Exp Med (1982) 1.92
Specific binding of the human S protein (vitronectin) to streptococci, Staphylococcus aureus, and Escherichia coli. Infect Immun (1987) 1.90
The membrane attack mechanism of complement: the three polypeptide chain structure of the eigth component (C8). J Exp Med (1976) 1.90
The alternative pathway of complement activation. Adv Immunol (1976) 1.87
Mechanism of action of factor D of the alternative complement pathway. J Exp Med (1978) 1.87
Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus. Immunochemistry (1973) 1.86
Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes. J Exp Med (1983) 1.83
Purification and partial characterization of human and porcine C3a anaphylatoxin. J Biol Chem (1975) 1.82
The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J Immunol (1978) 1.81
Immunochemical quantitation of the third, fourth and fifth components of human complement: concentrations in the serum of healthy adults. J Immunol (1967) 1.79
Physico-chemical characteristics of the third and fourth component of complement after dissociation from complement-cell complexes. Immunology (1967) 1.79
Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem (1988) 1.77
Membrane attack complex of complement: generation of high-affinity phospholipid binding sites by fusion of five hydrophilic plasma proteins. Proc Natl Acad Sci U S A (1979) 1.76
Immunofluorescent localization of the third and the fourth component of complement in synovial tissue from patients with rheumatoid arthritis. J Lab Clin Med (1967) 1.76
Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components. J Immunol (1978) 1.76
The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med (1996) 1.72
Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry (1976) 1.71
Circular polymerization of the ninth component of complement. Ring closure of the tubular complex confers resistance to detergent dissociation and to proteolytic degradation. J Biol Chem (1982) 1.70
Complement-immunoglobulin relation: deficiency of C'1q associated with impaired immunoglobulin G synthesis. Science (1969) 1.67
The serine protease nature of the C3 and C5 convertases of the classical and alternative complement pathways. Scand J Immunol (1976) 1.67